Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin

Pepper, Christopher John, Ward, R., Lin, Thet Thet, Brennan, Paul ORCID: https://orcid.org/0000-0001-8792-0499, Starczynski, J., Musson, M., Rowntree, Claire, Bentley, P., Mills, K., Pratt, G. and Fegan, Christopher Daniel ORCID: https://orcid.org/0000-0001-9685-0621 2007. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 21 (4) , pp. 687-696. 10.1038/sj.leu.2404587

Full text not available from this repository.

Abstract

CD38 expression is an important prognostic marker in chronic lymphocytic leukemia (CLL) with high levels of CD38 associated with shorter overall survival. In this study, we used gene expression profiling and protein analysis of highly purified cell-sorted CD38(+) and CD38(-) chronic lymphocytic leukemia cells to elucidate a molecular basis for the association between CD38 expression and inferior clinical outcome. Paired CD38(+) and CD38(-) CLL cells derived from the same patient were shown to be monoclonal by V(H) gene sequencing but despite this, CD38(+) CLL cells possessed a distinct gene expression profile when compared with their CD38(-) sub-clones. Importantly, CD38(+) CLL cells relatively over expressed vascular endothelial growth factor (VEGF) and appeared to preferentially utilize an internal autocrine VEGF survival loop. Elevated VEGF expression was associated with increased expression of the anti-apoptotic protein Mcl-1. Inhibition of VEGF receptor signaling also resulted in a reduction in cell viability. In contrast, exogenous VEGF caused a significant increase in CD38(-) CLL cell viability and a marked induction of Mcl-1; both effects were less obvious in CD38(+) CLL cells. Taken together, our data provide a biological rationale for the poor prognosis of CD38(+) CLL and indicate that both VEGF and Mcl-1 may prove to be useful therapeutic targets.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	Antigens CD/blood,Antigens CD/genetics,Antigens CD38/blood*,Antigens CD38/deficiency*,AntigensCd38/genetics,GeneExpressionRegulationNeoplastic*,Humans,Immunoglobulin Heavy Chains/genetics,Immunoglobulin Variable Region/genetics,Leukemia Lymphocytic Chronic,B-Cell/genetics*,Leukemia, Lymphocytic, Chronic,B-Cell/immunology*,Leukemia Lymphocytic Chronic,B-Cell/mortality,Oligonucleotide Array Sequence Analysis,Restriction Mapping,Survival Analysis,Vascular Endothelial Growth Factor A/genetics Substances AntigensCD,Immunoglobulin Heavy Chains,Immunoglobulin Variable Region,Vascular Endothelial Growth Factor A,Antigens, CD38
Additional Information:	Publication Types Research Support, Non-U.S. Gov't Full Text Sources Nature Publishing Group EBSCO Ovid Technologies, Inc. ProQuest Other Literature Sources COS Scholar Universe Labome Researcher Resource - ExactAntigen/Labome
Publisher:	Nature Publishing Group
ISSN:	0887-6924
Last Modified:	25 Oct 2022 09:24
URI:	https://orca.cardiff.ac.uk/id/eprint/58340

Citation Data

Cited 49 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item